<DOC>
	<DOC>NCT00110357</DOC>
	<brief_summary>The purpose of this clinical research study is to establish the maximum tolerated dose and recommended Phase II dose of Erbitux™ in combination with Irinotecan in pediatric and adolescent patients with refractory solid tumors.</brief_summary>
	<brief_title>Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically or cytologically confirmed diagnosis of a solid tumor which has progressed on, or following standard therapy, or for which no standard effective therapy is known. Children age 118 years. Presence of active infection. Requirement to receive concurrent chemotherapy immunotherapy, radiotherapy, or any other investigational drug while on study. Inadequate bone marrow, hepatic, or renal function.</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>